Indeed, on a positive note, another recent work has shown that long-term treatment with Mogamulizumab leads to the restoration of immunity in SS and MF patients through the elimination of exhausted T lymphocytes and the re-appearance of CD8 and CD4 memory T cells [18]. The gene discussed is CD8A; the disease is synovial sarcoma.